This table shows the list known insiders, and is generated automatically from filings disclosed to the SEC. In addition to the names, most recent title, and director, officer, or 10% owner designation, we provide the latest disclosed holdings.
| Name | Shares | Options |
|---|---|---|
| BIOTECH TARGET N V | 8,733,538 | 0 |
| BIOTECH GROWTH N V | 6,881,685 | 0 |
| Rubric Capital Management LP | 6,812,620 | 0 |
| Bain Capital Public Equity Management, LLC | 1,943,241 | 0 |
| F2 Bioscience IV L.P. | 587,500 | 0 |
| Jovan-Embiricos Morana By Fund | 587,500 | 0 |
| Carmona Jose | 46,708 | 0 |
| Morris Charles Q | 33,744 | 0 |
| Kelly Joseph Francis | 24,111 | 0 |
| Hoiland Jesper | 12,900 | 0 |
| Hopfield Jessica | 12,800 | 0 |
| Rosenberg Anthony | 12,401 | 0 |
| Dere Willard H | 12,195 | 0 |
| Grausso Sal | 11,709 | 0 |
| Hughes Owen | 10,650 | 0 |
| Chopas James George | 6,701 | 0 |
| Snow David P. | 6,000 | 0 |
| Graves Kurt | 5,500 | 0 |
| Roychowdhury Debasish | 5,500 | 0 |
| Hatzis-Schoch Brent | 2,278 | 0 |
| Purandare Dinesh | 200 | 0 |
| Fitzpatrick Lorraine A. | 200 | 0 |
| Shah Chhaya | 0 | 0 |
| FRIEDMAN CATHY | 0 | 0 |
| Martin G. Kelly | 0 | 0 |
| Messersmith Elizabeth | 0 | 0 |
| GADICKE ANSBERT | 0 | 0 |
| Stoner Elizabeth | 0 | 0 |
| GADICKE ANSBERT By Fund | 0 | 0 |
| Murphy Sean | 0 | 0 |
| VON ESCHENBACH ANDREW C. | 0 | 0 |
| MPM BioVentures IV LLC | 0 | 0 |
| F2 Bioscience IV GP Ltd. | 0 | 0 |
| Jovan-Embiricos Morana | 0 | 0 |
| F2 Capital Ltd | 0 | 0 |
| Yates John | 0 | 0 |
| Holtschlag Danielle | 0 | 0 |
| Helwig Steven | 0 | 0 |
| Muenchbach Martin By Fund | 0 | 0 |
| F2 Bioscience III, L.P. | 0 | 0 |
| Muenchbach Martin | 0 | 0 |
| Durand Mark | 0 | 0 |
| Nordic Bioscience Clinical Development VII A/S | 0 | 0 |
| Fromkin Andrew J. | 0 | 0 |
| Conley Mark William | 0 | 0 |
| Lisa Susan Vissers | 0 | 0 |
| Ward Robert | 0 | 0 |
| MPM BIOVENTURES III LLC | 0 | 0 |
| F2 Bioscience IV L.P. By Fund | 0 | 0 |
| CAVANAUGH JAMES H | 0 | 0 |
| Jarrett Jennifer | 0 | 0 |
| AUERBACH ALAN H | 0 | 0 |
| Williams Gregory C. | 0 | 0 |
| EVNIN LUKE | 0 | 0 |
| BB BIOTECH AG | 0 | 0 |
| BRENNER LOUIS MD | 0 | 0 |
| WYZGA MICHAEL S | 0 | 0 |
| Franken Michael | 0 | 0 |
| Lyttle Cecil Richard | 0 | 0 |
| HARRIS ALAN G | 0 | 0 |
| Harvey Brian Nicholas | 0 | 0 |
| Muenchbach Martin By Fund | 0 | 0 |
| GALAKATOS NICHOLAS | 0 | 0 |
| SANDERS MACHELLE | 0 | 0 |
| 0 | 0 | |
| Hattersley Gary | 0 | 0 |
| Dolan Dan | 0 | 0 |
| GARNIER JEAN PIERRE | 0 | 0 |
While Insider sales are normal part of tax harvesting and is part of compensation of executives - A large number of transactions would indicate that the management isnt convinced that the price will go up and hence reducing their holding. This would be a possible indicator or fall in price
| Name | Shares | Price | Date |
|---|
Insider buys arent usual, since it indicates a high conviction by the management that they believe the price will go up eventually. Usually a good sign that investors should consider this as a factor to purchase a stock, especially if the current SP is lower than the price the management bought these at. The table below doesnt include any Stock Options or RSUs. They're just open market purchases by the insiders.
| Name | Shares | Price | Date |
|---|---|---|---|
| BIOTECH TARGET N V | 477,824 | 5.57 | 2022 May 18 |